AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Skyrizi is currently under review with the US Food and Drug Administration (FDA), and AbbVie expects a regulatory decision in the first half of this year. Approval in Europe is also highly likely ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...